Navigation Links
Circulation Publishes MERLIN TIMI-36 Data Showing Safety and Anti-Arrhythmic Effects of Ranexa(R)
Date:9/5/2007

ent. The doses of Ranexa extended-release tablets used in MERLIN TIMI-36 have been studied in previous Phase 3 clinical trials.

Participants in the MERLIN TIMI-36 study received modern therapy, with approximately 96 percent of patients on aspirin, approximately 89 percent on beta blockers and approximately 82 percent on statins. Approximately 59 percent of study participants received coronary angiography during their initial hospitalization.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.

CV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets), is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.

CV Therapeutics also has other clinical and preclinical drug development candidates and programs, including regadenoson, which is being developed for potential use as a pharmacologic stress agent in myocardial perfusion imaging studies, and CVT-6883, which is being developed as a potential treatment for cardiopulmonary diseases. Regadenoson and CVT-6883 have not been determined by any regulatory authorities to be safe or effective in humans for any use.

Except for the historical information contained herein, the matters set forth in this press release, including statements as to clinical trials and regulatory filings, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including operating losses and fluctuations in
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Third coast of biotechnology makes strong showing at VC conference
2. Reforming FDA: Focus on safety, let market judge efficacy
3. Funds will support public safety communications interoperabilty
4. High interest forces delay in food safety symposium
5. Human factors and IT: Designing for patient safety
6. UW Medical Foundation CEO shares his vision on the state of health care and patient safety
7. UW symposium to explore impact of IT on improving quality, safety and cost of healthcare
8. Thompson receives leadership award for technology solutions for patient safety
9. Effects of Thermal Cycler Well-To-Well Temperature Uniformity on PCR Results
10. Measuring Gene Silencing Effects by RT-PCR Without RNA Isolation
11. Confirming RNAi Effects Is Now Easier Than Ever
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Canada (PRWEB) July 10, 2014 ... present in very low abundance and are often ... challenging and time-consuming. , Join presenters Dr. Rowel ... and Dr. John Anders, Head of Quality at ... spectrometer-based approach that can speed detection and quantitation ...
(Date:7/10/2014)... Poway, CA (PRWEB) July 10, 2014 Robert ... Regenerative Veterinary Medicine company, is proud to announce the relaunch ... Pets, launching with a new series called “ What are ... to give an honest and straightforward foundation in the basics ... an educated decision on the right type of treatment when ...
(Date:7/10/2014)... On July 9 Prime Minister ... Russia,s first national "Industry" award ... is developing a unique project called MabNext . ... number of innovative drugs based on monoclonal antibodies for ... place at the International Exhibition "Innoprom 2014" in Ekaterinburg. ...
(Date:7/10/2014)... -- According to the International Atomic Energy Agency ... from terrorists acquiring sufficient quantities of plutonium or ... nuclear explosive device. The IAEA also notes that ... gram-level quantities, which can be challenging to detect ... new study appearing this week in the ...
Breaking Biology Technology:Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2Sensitive detection method may help impede illicit nuclear trafficking 2
... , MOUNTAIN VIEW, Calif., Aug. 26 ... a special meeting of stockholders held today, its stockholders approved the ... to purchase shares of the Company,s common stock to Symphony Capital ... completed its acquisition of Symphony Allegro, and as a result, Alexza ...
... , , , ... ) and Terrabon, L.L.C., today announced an agreement by Waste Management ... is the leading provider of comprehensive waste management and environmental services ... Management joins Valero Energy Corporation (NYSE: VLO ), the ...
... a valuable source of biofuel. Researchers writing in BioMed ... have shown that the juice of reject watermelons can ... with a team of researchers at the USDA-Agricultural Research ... US, to evaluate the biofuel potential of juice from ...
Cached Biology Technology:Alexza Stockholders Approve Share Issuance to Symphony Capital and Alexza Completes Acquisition of Symphony Allegro 2Alexza Stockholders Approve Share Issuance to Symphony Capital and Alexza Completes Acquisition of Symphony Allegro 3Alexza Stockholders Approve Share Issuance to Symphony Capital and Alexza Completes Acquisition of Symphony Allegro 4Waste Management and Terrabon Announce Investment Agreement for Waste-To-Fuel Conversion Technology 2Waste Management and Terrabon Announce Investment Agreement for Waste-To-Fuel Conversion Technology 3Waste Management and Terrabon Announce Investment Agreement for Waste-To-Fuel Conversion Technology 4
(Date:7/10/2014)... Amyloid diseases, such as Alzheimer,s disease, type ... share the common trait that proteins aggregate into ... vitro studies have found that neither the amylin ... toxic. New evidence using two-dimensional infrared (2D IR) ... amylin aggregation pathway that may explain toxicity, opening ...
(Date:7/10/2014)... Geostationary Operational Environmental Satellite or GOES-West satellite spotted ... fires raging in Canada,s Northwestern Territories. , At ... 2014, GOES-West captured this image of the brownish-colored ... Territories that drifted all the way into South ... GOES Project at NASA Goddard Space Flight Center, ...
(Date:7/10/2014)... MDBrightFocus Foundation, a nonprofit organization funding cutting-edge, innovative ... of glaucoma and macular degeneration, today announced the ... 55 scientists in 19 U.S. states, the District ... http://www.brightfocus.org/Grants2014 . , With these latest grants, ... in research funding in 2014. , The research ...
Breaking Biology News(10 mins):New technology reveals insights into mechanisms underlying amyloid diseases 2BrightFocus Foundation announces 55 new grantees in Alzheimer's and vision research 2BrightFocus Foundation announces 55 new grantees in Alzheimer's and vision research 3
... in the brain that help make HIV disease incurable, scientists ... biological vacuum cleaner that prevents anti-HIV drugs from reaching the ... HIV. They describe the advance, which allows medications to cross ... the Journal of the American Chemical Society . ...
... 12 October 2011, Singapore A new biotech ... of Singapore (NUS), to provide research tools, targeting the ... has been founded by two NUS faculty members: Dr ... Dr Kevin Tan from the NUS Department of Microbiology. ...
... carbon dioxide than it can bind. Local variations have increased the ... a study of how carbon dioxide flows between the water of ... the University of Gothenburg, Sweden. "The capacity of the ... acidity of the water has changed in recent centuries. In the ...
Cached Biology News:Launch of BioLynx provides a boost for the international malaria research community 2The Baltic Sea contributes carbon dioxide to the atmosphere 2
casein kinase 2, alpha 1 polypeptide, transcript variant 2, mRNA (cDNA clone MGC:15232 IMAGE:4121882), complete cds...
...
UV LAMP 300 NM 8W T5, 1 EA. Category: Nucleid Acid Detection Systems....
MOUSE ANTI S. MUTANS PEPTIDOGLYCAN...
Biology Products: